This report presents the results of a survey of 899 DMPA acceptors who availed of injectable contraceptive services from public health facilities under the Philippine Department of Health's (DOH) DMPA Reintroduction Program. The survey is part of the DMPA Monitoring and Follow-up Studies sponsored by the Population Council’s Manila office in response to a request by the DOH to provide operations research support to the program. Depot-medroxyprogesterone acetate (DMPA), commonly known as Depo-Provera, is a three-month injectable contraceptive. It was recently officially endorsed as a family planning (FP) program method by the DOH, following its approval by the Philippine Bureau of Food and Drugs in November 1993. DMPA as a program method was launched by the DOH in April 1994 in six provinces and four chartered cities spread throughout seven administrative regions in the Philippines. The program aims to reintroduce DMPA into the Philippine Family Planning Program via the training of local-level midwives, nurses, and doctors as DMPA service providers, and by the provision of free DMPA services in selected public health facilities nationwide.
Patron, Maria Carmela and Marilou Palabrica-Costello. 1995. "Experience with the DMPA injectable contraceptive: Findings from a survey of DMPA acceptors," Asia & Near East Operations Research and Technical Assistance Project Special Report. Manila: Population Council, Department of Health, and Family Planning Operations Research and Training Program.
Asia & Near East Operations Research and Technical Assistance Project